Description: <b>Hormone replacement therapy</b> <br>
<p><b>Hormone replacement therapy</b> — Menopausal hormone therapy (MHT), historically termed hormone replacement therapy (HRT), is the therapeutic administration of estrogen with or without a progestogen to replace declining ovarian sex-steroid activity during peri- or postmenopause. It is a systemic or local hormonal drug modality rather than a single molecular agent; common components include 17β-estradiol, conjugated equine estrogens (CEE), micronized progesterone, and synthetic progestins such as medroxyprogesterone acetate (MPA). Standard abbreviations are HRT, HT, MHT, ET for estrogen therapy, and EPT for estrogen-progestogen therapy. Estrogen alone is generally used after hysterectomy, whereas women with an intact uterus receiving systemic estrogen ordinarily require adequate progestogen-mediated endometrial protection. Cancer effects are strongly formulation-, tissue-, duration-, age-, and timing-dependent: HRT should not be classified globally as either cancer-promoting or cancer-protective.</p>
<p><b>Primary mechanisms (ranked):</b></p>
<ol>
<li>Estrogen receptor signaling — estradiol and related estrogens activate ERα and ERβ transcriptional programs; in ER-responsive breast and endometrial tissue this can promote proliferation and survival, although biological effects differ by tissue and hormonal context.</li>
<li>Progesterone receptor signaling and endometrial opposition — progesterone or progestins activate PR and oppose estrogen-driven endometrial proliferation, markedly reducing the endometrial hyperplasia/cancer risk produced by unopposed systemic estrogen.</li>
<li>Breast epithelial proliferation — combined estrogen-progestogen therapy, particularly the CEE plus MPA regimen studied in WHI, increases breast cancer incidence with sufficiently prolonged exposure; the effect is not equivalent to estrogen-alone therapy.</li>
<li>Tissue-selective steroid receptor effects — breast, endometrium, ovary, bone, brain, vasculature, liver, and genitourinary tissues respond differently to estrogen/progestogen exposure, producing divergent benefit-risk profiles.</li>
<li>Hepatic first-pass signaling — oral estrogen increases hepatic exposure and alters synthesis of coagulation, lipid, inflammatory, and hormone-binding proteins more strongly than transdermal estradiol; this contributes to route-dependent systemic effects.</li>
</ol>
<p><b>Bioavailability / PK relevance:</b> HRT exposure depends strongly on molecule and route. Oral estradiol undergoes substantial intestinal/hepatic first-pass metabolism with relatively high estrone and hepatic protein effects. Transdermal estradiol bypasses first-pass hepatic exposure and generally produces more physiologic estradiol-to-estrone profiles. Vaginal low-dose estrogen is intended primarily for local genitourinary effects and usually produces much lower systemic exposure than systemic HRT. Progestogen pharmacology also matters; micronized progesterone and synthetic progestins are not pharmacologically interchangeable.</p>
<p><b>In-vitro vs systemic exposure relevance:</b> HRT is concentration-driven through steroid-receptor occupancy, but clinically relevant effects occur at physiological or near-physiological systemic hormone concentrations rather than the high micromolar exposures commonly used in experimental cancer-cell studies. Mechanistic conclusions from high-concentration estradiol or progestin experiments should therefore not automatically be extrapolated to menopausal dosing.</p>
<p><b>Clinical evidence status:</b> Extensive human evidence including large randomized controlled trials and decades of clinical use. HRT is established for menopausal vasomotor symptoms and genitourinary indications and can prevent bone loss in appropriate patients; it is not an anticancer therapy. Cancer effects differ substantially by regimen. WHI randomized evidence shows increased breast cancer incidence with CEE plus MPA, whereas CEE alone in women with prior hysterectomy was associated with lower breast cancer incidence and mortality during long-term follow-up. Unopposed systemic estrogen increases endometrial cancer risk in women with a uterus, while adequate combined estrogen-progestogen therapy substantially suppresses this risk. Current prescribing therefore requires individualized assessment of formulation, route, age, time since menopause, uterus status, prior hormone-sensitive malignancy, cardiovascular and thromboembolic risk, and treatment indication.</p>
<h3>HRT Cancer-Relevant Mechanisms</h3>
<table>
<thead>
<tr>
<th>Rank</th>
<th>Pathway / Axis</th>
<th>Cancer Cells</th>
<th>Normal Cells</th>
<th>TSF</th>
<th>Primary Effect</th>
<th>Notes / Interpretation</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Estrogen receptor ERα signaling</td>
<td>↑ in ER-positive tumors</td>
<td>↑</td>
<td>R/G</td>
<td>Transcriptional activation and proliferation</td>
<td>Central estrogen mechanism. ERα activation can support proliferation and survival of hormone-responsive breast and endometrial cells; effects are tissue- and hormonal-context dependent.</td>
</tr>
<tr>
<td>2</td>
<td>Breast epithelial proliferation</td>
<td>↑ with estrogen plus progestogen (regimen-dependent)</td>
<td>↑</td>
<td>G</td>
<td>Increased proliferative signaling</td>
<td>Clinically most important cancer liability of combined systemic HRT. WHI CEE plus MPA increased breast cancer incidence; this should not be generalized to estrogen-alone therapy.</td>
</tr>
<tr>
<td>3</td>
<td>Progesterone receptor signaling</td>
<td>↑ (context-dependent)</td>
<td>↑</td>
<td>R/G</td>
<td>Modifies estrogen-responsive transcription and differentiation</td>
<td>Progestogens protect the endometrium but may contribute to the breast-risk difference between combined therapy and estrogen alone. Effects differ among progesterone and synthetic progestins.</td>
</tr>
<tr>
<td>4</td>
<td>Endometrial proliferation</td>
<td>↑ with unopposed estrogen</td>
<td>↑ with unopposed estrogen</td>
<td>G</td>
<td>Endometrial growth and hyperplasia</td>
<td>Unopposed systemic estrogen is a well-established endometrial cancer risk in women with an intact uterus.</td>
</tr>
<tr>
<td>5</td>
<td>Progestogen-mediated endometrial protection</td>
<td>↓ estrogen-driven proliferation</td>
<td>↓ estrogen-driven proliferation</td>
<td>G</td>
<td>Endometrial differentiation and antiproliferative opposition</td>
<td>Adequate progesterone/progestin exposure strongly reduces the endometrial hyperplasia and cancer risk associated with systemic estrogen.</td>
</tr>
<tr>
<td>6</td>
<td>Breast cancer incidence</td>
<td>↑ with CEE plus MPA</td>
<td>Not applicable</td>
<td>G</td>
<td>Regimen-dependent cancer risk</td>
<td>Randomized WHI follow-up supports increased breast cancer incidence with combined CEE plus MPA. Risk increases with duration in large observational datasets.</td>
</tr>
<tr>
<td>7</td>
<td>Breast cancer incidence with estrogen alone</td>
<td>↓ in WHI CEE-alone population</td>
<td>Not applicable</td>
<td>G</td>
<td>Reduced breast cancer incidence in a specific clinical population</td>
<td>Observed in randomized WHI participants with prior hysterectomy receiving CEE alone; this finding should not be generalized to all estrogens, doses, populations, or women with an intact uterus.</td>
</tr>
<tr>
<td>8</td>
<td>Endometrial cancer incidence with combined therapy</td>
<td>↓</td>
<td>Not applicable</td>
<td>G</td>
<td>Reduced endometrial cancer risk</td>
<td>Continuous combined estrogen plus progestin reduced endometrial cancer incidence in WHI follow-up.</td>
</tr>
<tr>
<td>9</td>
<td>Ovarian cancer risk</td>
<td>↑ (regimen-dependent)</td>
<td>Not applicable</td>
<td>G</td>
<td>Possible increased incidence</td>
<td>Long-term WHI follow-up reported increased ovarian cancer incidence and mortality with CEE alone; findings differ between estrogen-alone and combined regimens.</td>
</tr>
<tr>
<td>10</td>
<td>Colorectal cancer outcome</td>
<td>↔ / mixed</td>
<td>Not applicable</td>
<td>G</td>
<td>No established therapeutic benefit</td>
<td>Although early WHI analyses showed fewer diagnoses with CEE plus MPA, longer evaluation does not support a clinically meaningful colorectal cancer benefit.</td>
</tr>
<tr>
<td>11</td>
<td>Lung cancer outcome</td>
<td>↔ incidence; ↑ mortality signal with CEE plus MPA</td>
<td>Not applicable</td>
<td>G</td>
<td>Regimen-dependent adverse signal</td>
<td>WHI analyses found increased lung-cancer mortality during combined CEE plus MPA exposure despite no clear increase in incidence, arguing against classifying HRT globally as reducing cancer risk.</td>
</tr>
<tr>
<td>12</td>
<td>Clinical Translation Constraint</td>
<td>↔</td>
<td>↔</td>
<td>G</td>
<td>Strong dependence on regimen and patient context</td>
<td>Estrogen alone versus combined therapy, estrogen type, progestogen type, route, dose, duration, age, time since menopause, uterus status, and prior hormone-sensitive cancer materially alter the benefit-risk profile.</td>
</tr>
</tbody>
</table>
<p>P: 0–30 min R: 30 min–3 hr G: >3 hr</p>
<br><br>
<p><b>Alzheimer’s disease relevance:</b> Menopausal hormone therapy has substantial mechanistic and clinical relevance to cognition but is not an established treatment or prevention strategy for Alzheimer’s disease. Estrogen receptors are widely expressed in the brain and estrogen can influence synaptic plasticity, glucose metabolism, mitochondrial function, cholinergic signaling, cerebral blood flow, and amyloid-related biology. However, randomized clinical evidence has not demonstrated reliable cognitive or dementia prevention benefit. In WHIMS, initiation of CEE plus MPA in women aged 65 years or older increased probable dementia, and CEE alone did not prevent dementia. Trials beginning therapy closer to menopause, including KEEPS-Cog and ELITE-Cog, generally found neither meaningful cognitive benefit nor major cognitive harm. Timing, formulation, age, and baseline vascular/neurodegenerative status appear important, but HRT should not currently be classified as an Alzheimer’s disease therapy.</p>
<h3>HRT Alzheimer’s-Relevant Mechanisms</h3>
<table>
<thead>
<tr>
<th>Rank</th>
<th>Pathway / Axis</th>
<th>Modulation</th>
<th>TSF</th>
<th>Primary Effect</th>
<th>Notes / Interpretation</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Neuronal estrogen receptor signaling</td>
<td>↑</td>
<td>R/G</td>
<td>Neurotranscriptional and synaptic regulation</td>
<td>Estradiol activates ERα, ERβ, and membrane-associated estrogen signaling throughout cognition-relevant brain regions.</td>
</tr>
<tr>
<td>2</td>
<td>Synaptic plasticity</td>
<td>↑ (context-dependent)</td>
<td>G</td>
<td>Supports synaptic structure and signaling</td>
<td>Strong experimental rationale, but improved synaptic biology has not translated into established dementia prevention in randomized trials.</td>
</tr>
<tr>
<td>3</td>
<td>Brain glucose and mitochondrial metabolism</td>
<td>↑ (context-dependent)</td>
<td>G</td>
<td>Metabolic support</td>
<td>Estrogen can enhance neuronal bioenergetic pathways; effects may depend on timing relative to menopause and underlying metabolic state.</td>
</tr>
<tr>
<td>4</td>
<td>Cholinergic signaling</td>
<td>↑ (model-dependent)</td>
<td>G</td>
<td>Supports acetylcholine-related neurotransmission</td>
<td>Mechanistically plausible and well described experimentally, but insufficient as evidence for clinical AD prevention.</td>
</tr>
<tr>
<td>5</td>
<td>Amyloid-related biology</td>
<td>↓ (model-dependent)</td>
<td>G</td>
<td>Potential reduction of amyloidogenic processes</td>
<td>Preclinical and biomarker observations exist, but randomized clinical evidence does not establish an anti-amyloid therapeutic effect.</td>
</tr>
<tr>
<td>6</td>
<td>Cognition in recently menopausal women</td>
<td>↔</td>
<td>G</td>
<td>No consistent cognitive improvement</td>
<td>KEEPS-Cog and ELITE-Cog found no meaningful overall cognitive benefit from initiation near menopause.</td>
</tr>
<tr>
<td>7</td>
<td>Dementia risk with late initiation</td>
<td>↑</td>
<td>G</td>
<td>Increased probable dementia in older initiators</td>
<td>WHIMS demonstrated increased probable dementia with CEE plus MPA initiated at age 65 years or older; estrogen alone also failed to provide dementia protection.</td>
</tr>
<tr>
<td>8</td>
<td>Clinical Translation Constraint</td>
<td>↔</td>
<td>G</td>
<td>No established AD indication</td>
<td>Potential effects depend on age, timing after menopause, formulation, vascular health, APOE and other biological context. HRT should not be initiated specifically to prevent or treat Alzheimer’s disease.</td>
</tr>
</tbody>
</table>
<p>P: 0–30 min R: 30 min–3 hr G: >3 hr</p>